Review Article
Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
Table 2
Phase 3 clinical trials of erlotinib in colorectal cancer.
| Study | Number of enrollment | Expected date of completion | NCT identifier |
| Chemotherapy and Avastin followed by maintenance treatment with Avastin Tarceva | 240 | December 2011 | NCT 00598156 | Combination chemotherapy and bevacizumab erlotinib in unresectable mCRC | 640 | Unknown | NCT00265824 |
|
|